Thrombocytopenia differential diagnosis: Difference between revisions
No edit summary |
|||
Line 182: | Line 182: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 212: | Line 212: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 548: | Line 548: | ||
| align="center" style="background:#F5F5F5;" + |Antibody-mediated platelet destruction | | align="center" style="background:#F5F5F5;" + |Antibody-mediated platelet destruction | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 578: | Line 578: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 608: | Line 608: | ||
| align="center" style="background:#F5F5F5;" + |Autoantibody-mediated syndrome | | align="center" style="background:#F5F5F5;" + |Autoantibody-mediated syndrome | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 639: | Line 639: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 669: | Line 669: | ||
! align="center" style="background:#DCDCDC;" + |Sepsis | ! align="center" style="background:#DCDCDC;" + |Sepsis | ||
| align="center" style="background:#F5F5F5;" + |Direct bone marrow suppression | | align="center" style="background:#F5F5F5;" + |Direct bone marrow suppression | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 700: | Line 700: | ||
| align="center" style="background:#F5F5F5;" + |Immune thrombocytopenia | | align="center" style="background:#F5F5F5;" + |Immune thrombocytopenia | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 730: | Line 730: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 763: | Line 763: | ||
* An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT) | * An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT) | ||
* Secondary opportunistic infections | * Secondary opportunistic infections | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 793: | Line 793: | ||
! align="center" style="background:#DCDCDC;" + |Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus | ! align="center" style="background:#DCDCDC;" + |Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 928: | Line 928: | ||
* Quinine | * Quinine | ||
| align="center" style="background:#F5F5F5;" + |Occurrence of drug-dependent, platelet-reactive antibodies | | align="center" style="background:#F5F5F5;" + |Occurrence of drug-dependent, platelet-reactive antibodies | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 959: | Line 959: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 988: | Line 988: | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Cytotoxic chemotherapy | ! colspan="2" align="center" style="background:#DCDCDC;" + |Cytotoxic chemotherapy | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,018: | Line 1,018: | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Radiation therapy | ! colspan="2" align="center" style="background:#DCDCDC;" + |Radiation therapy | ||
| align="center" style="background:#F5F5F5;" + |Predictable, dose-dependent myelosuppression | | align="center" style="background:#F5F5F5;" + |Predictable, dose-dependent myelosuppression | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,080: | Line 1,080: | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Chronic liver disease | ! colspan="2" align="center" style="background:#DCDCDC;" + |Chronic liver disease | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,174: | Line 1,174: | ||
| align="center" style="background:#F5F5F5;" + |Platelet destruction | | align="center" style="background:#F5F5F5;" + |Platelet destruction | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,204: | Line 1,204: | ||
| align="center" style="background:#F5F5F5;" + |Platelet destruction | | align="center" style="background:#F5F5F5;" + |Platelet destruction | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,234: | Line 1,234: | ||
| align="center" style="background:#F5F5F5;" + |Platelet destruction | | align="center" style="background:#F5F5F5;" + |Platelet destruction | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,264: | Line 1,264: | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Alcohol | ! colspan="2" align="center" style="background:#DCDCDC;" + |Alcohol | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,295: | Line 1,295: | ||
| align="center" style="background:#F5F5F5;" + |Immune mediated platelet destruction | | align="center" style="background:#F5F5F5;" + |Immune mediated platelet destruction | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | |
Revision as of 23:26, 14 August 2018
Thrombocytopenia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Thrombocytopenia differential diagnosis On the Web |
American Roentgen Ray Society Images of Thrombocytopenia differential diagnosis |
Risk calculators and risk factors for Thrombocytopenia differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farbod Zahedi Tajrishi, M.D.
Overview
Thrombocytopenia has a broad range of potential causes. While a good history and physical examination can be helpful to diagnose some of these causes such as drug-induced thrombocytopenia, they usually don't suffice and further evaluation is often needed. There are also some useful points that may guide the physician to an appropriate diagnosis. For example, asymptomatic, isolated thrombocytopenia most probably suggests ITP, while thrombocytopenia in critically ill, hospitalized patients is usually suggestive of iatrogenic causes (eg. dilution), platelet consumption, bone marrow suppression from infection/sepsis, or even drug-induced thrombocytopenia. One should consider however, that a wide variety of other conditions such as autoimmune disorders, nutrient deficiencies, thrombotic microangiopathies could all as well cause thrombocytopenia.
Thrombocytopenia Differential Diagnosis
Differentiating the diseases that can cause thrombocytopenia:
Category | Condition | Mechanism | Mechanism | Inherited | Acquried | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age range | History | Symptoms | Signs | |||||||||||||||||||||||||||
Lab Findings | Imaging | |||||||||||||||||||||||||||||
Severity | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other | CBC | PBS | Bone marrow exam | PT | PTT | BT | UA | ||||||||||||||||
Decreased platelet production | Platelet destruction in bloodstream | Platelet destruction in spleen/liver | Plt | HB | WBC | |||||||||||||||||||||||||
Hematology | Bone marrow disorders | Myelodysplastic syndromes | + | |||||||||||||||||||||||||||
Aplastic anemia | + | |||||||||||||||||||||||||||||
Acute leukemia | + | |||||||||||||||||||||||||||||
Paroxysmal nocturnal hemoglobinuria (PNH) | + | |||||||||||||||||||||||||||||
Thrombotic microangiopathy (TMA) | Thrombotic thrombocytopenic purpura (TTP) | + | ||||||||||||||||||||||||||||
Hemolytic uremic syndrome (HUS) | + | |||||||||||||||||||||||||||||
DIC | + | |||||||||||||||||||||||||||||
Congenital platelet disorders | MYH-9 related disorders | |||||||||||||||||||||||||||||
Bernard-Soulier syndrome | ||||||||||||||||||||||||||||||
Gray platelet syndrome | ||||||||||||||||||||||||||||||
Wiskott-Aldrich syndrome | ||||||||||||||||||||||||||||||
Thrombocytopenia with absent radius (TAR) syndrome | ||||||||||||||||||||||||||||||
Alport syndrome | ||||||||||||||||||||||||||||||
Von Willebrand disease | ||||||||||||||||||||||||||||||
Nutrient deficiencies | Folate, vitamin B12, copper | + | ||||||||||||||||||||||||||||
Category | Condition | Mechanism | Decreased platelet production | Platelet destruction in bloodstream | Platelet destruction in spleen/liver | Inherited | Acquried | Age range | History | Severity | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | BT | UA | Imaging | Gold standard | Associated findings | |
Rheumatologic/autoimmune disorders | Immune thrombocytopenia | Antibody-mediated platelet destruction | + | |||||||||||||||||||||||||||
Systemic lupus erythematosus (SLE) | + | |||||||||||||||||||||||||||||
Antiphospholipid syndrome (APS) | Autoantibody-mediated syndrome | + | ||||||||||||||||||||||||||||
Felty's syndrome | Splenomegaly | + | ||||||||||||||||||||||||||||
Infection-induced | Bacterial infections | Sepsis | Direct bone marrow suppression | + | + | |||||||||||||||||||||||||
Helicobacter pylori | Immune thrombocytopenia | + | ||||||||||||||||||||||||||||
Tick-borne infection | + | |||||||||||||||||||||||||||||
Viral infections | HIV |
|
+ | + | + | |||||||||||||||||||||||||
Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus | + | |||||||||||||||||||||||||||||
Intracellular parasites | Malaria | |||||||||||||||||||||||||||||
Babesiosis | ||||||||||||||||||||||||||||||
Category | Condition | Mechanism | Decreased platelet production | Platelet destruction in bloodstream | Platelet destruction in spleen/liver | Inherited | Acquried | Age range | History | Severity | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | BT | UA | Imaging | Gold standard | Associated findings | |
Medication/toxicity | Drug-induced immune thrombocytopenia |
|
Occurrence of drug-dependent, platelet-reactive antibodies | + | + | |||||||||||||||||||||||||
Heparin-induced thrombocytopenia | + | |||||||||||||||||||||||||||||
Cytotoxic chemotherapy | + | |||||||||||||||||||||||||||||
Radiation therapy | Predictable, dose-dependent myelosuppression | + | ||||||||||||||||||||||||||||
OTC agents | Quinine-containing beverages | |||||||||||||||||||||||||||||
GI | Chronic liver disease | + | ||||||||||||||||||||||||||||
Portal hypertension | ||||||||||||||||||||||||||||||
Category | Condition | Mechanism | Decreased platelet production | Platelet destruction in bloodstream | Platelet destruction in spleen/liver | Inherited | Acquried | Age range | History | Severity | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | BT | UA | Imaging | Gold standard | Associated findings | |
Vascular | Giant capillary hemangioma | Platelet destruction | + | |||||||||||||||||||||||||||
Aortic aneurysm | Platelet destruction | + | ||||||||||||||||||||||||||||
Cardiopulmonary bypass | Platelet destruction | + | ||||||||||||||||||||||||||||
Other | Alcohol | + | ||||||||||||||||||||||||||||
Post-transfusion purpura | Immune mediated platelet destruction | + | ||||||||||||||||||||||||||||
Gestational thrombocytopenia |